Effectiveness of Isoniazid Treatment for Latent Tuberculosis Infection among Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Injection Drug Users in Methadone Programs

Jerod N. Scholten, Cynthia R. Driver, Sonal S. Munsiff, Katherine Kaye, Mary Ann Rubino, Marc Gourevitch, Caroline Trim, James Amofa, Randy Seewald, Esther Highley, Paula I. Fujiwara

Research output: Contribution to journalArticle

Abstract

Injection drug users (IDUs) were heavily affected by the tuberculosis (TB) resurgence in New York City in the 1990s. We assessed the effectiveness of screening for latent TB infection in methadone users and of selective treatment with isoniazid. Risk for future TB was classified as low or high on the basis of tuberculin, anergy, and HIV test results. The cohort of 2212 IDUs was followed up for a median of 4.2 years; 25 IDUs, of whom 20 (80%) were infected with human immunodeficiency virus (HIV), developed TB. In an adjusted Cox proportional hazards model of high-risk IDUs, the risk of TB was associated with HIV infection (HR 10.3; 95% CI, 3.4-31.3); receipt of <6 months of isoniazid therapy (HR 7.6; 95% CI, 1.02-57.1); a CD4+ T lymphocyte count of <200 cells/mm3 (HR 6.6; 95% CI, 1.7-25.9); and tuberculin positivity (HR 4.0; 95% CI, 1.6-10.2). Treatment with isoniazid was beneficial in HIV-infected, tuberculin-positive IDUs.

Original languageEnglish (US)
Pages (from-to)1686-1692
Number of pages7
JournalClinical Infectious Diseases
Volume37
Issue number12
DOIs
StatePublished - Dec 15 2003

Fingerprint

Latent Tuberculosis
Methadone
Isoniazid
Drug Users
HIV
Tuberculin
Tuberculosis
Injections
Virus Diseases
CD4 Lymphocyte Count
Proportional Hazards Models
Therapeutics
T-Lymphocytes

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Effectiveness of Isoniazid Treatment for Latent Tuberculosis Infection among Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Injection Drug Users in Methadone Programs. / Scholten, Jerod N.; Driver, Cynthia R.; Munsiff, Sonal S.; Kaye, Katherine; Rubino, Mary Ann; Gourevitch, Marc; Trim, Caroline; Amofa, James; Seewald, Randy; Highley, Esther; Fujiwara, Paula I.

In: Clinical Infectious Diseases, Vol. 37, No. 12, 15.12.2003, p. 1686-1692.

Research output: Contribution to journalArticle

Scholten, Jerod N. ; Driver, Cynthia R. ; Munsiff, Sonal S. ; Kaye, Katherine ; Rubino, Mary Ann ; Gourevitch, Marc ; Trim, Caroline ; Amofa, James ; Seewald, Randy ; Highley, Esther ; Fujiwara, Paula I. / Effectiveness of Isoniazid Treatment for Latent Tuberculosis Infection among Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Injection Drug Users in Methadone Programs. In: Clinical Infectious Diseases. 2003 ; Vol. 37, No. 12. pp. 1686-1692.
@article{f633f049a4aa4e998a003e37d71dd64c,
title = "Effectiveness of Isoniazid Treatment for Latent Tuberculosis Infection among Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Injection Drug Users in Methadone Programs",
abstract = "Injection drug users (IDUs) were heavily affected by the tuberculosis (TB) resurgence in New York City in the 1990s. We assessed the effectiveness of screening for latent TB infection in methadone users and of selective treatment with isoniazid. Risk for future TB was classified as low or high on the basis of tuberculin, anergy, and HIV test results. The cohort of 2212 IDUs was followed up for a median of 4.2 years; 25 IDUs, of whom 20 (80{\%}) were infected with human immunodeficiency virus (HIV), developed TB. In an adjusted Cox proportional hazards model of high-risk IDUs, the risk of TB was associated with HIV infection (HR 10.3; 95{\%} CI, 3.4-31.3); receipt of <6 months of isoniazid therapy (HR 7.6; 95{\%} CI, 1.02-57.1); a CD4+ T lymphocyte count of <200 cells/mm3 (HR 6.6; 95{\%} CI, 1.7-25.9); and tuberculin positivity (HR 4.0; 95{\%} CI, 1.6-10.2). Treatment with isoniazid was beneficial in HIV-infected, tuberculin-positive IDUs.",
author = "Scholten, {Jerod N.} and Driver, {Cynthia R.} and Munsiff, {Sonal S.} and Katherine Kaye and Rubino, {Mary Ann} and Marc Gourevitch and Caroline Trim and James Amofa and Randy Seewald and Esther Highley and Fujiwara, {Paula I.}",
year = "2003",
month = "12",
day = "15",
doi = "10.1086/379513",
language = "English (US)",
volume = "37",
pages = "1686--1692",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Effectiveness of Isoniazid Treatment for Latent Tuberculosis Infection among Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Injection Drug Users in Methadone Programs

AU - Scholten, Jerod N.

AU - Driver, Cynthia R.

AU - Munsiff, Sonal S.

AU - Kaye, Katherine

AU - Rubino, Mary Ann

AU - Gourevitch, Marc

AU - Trim, Caroline

AU - Amofa, James

AU - Seewald, Randy

AU - Highley, Esther

AU - Fujiwara, Paula I.

PY - 2003/12/15

Y1 - 2003/12/15

N2 - Injection drug users (IDUs) were heavily affected by the tuberculosis (TB) resurgence in New York City in the 1990s. We assessed the effectiveness of screening for latent TB infection in methadone users and of selective treatment with isoniazid. Risk for future TB was classified as low or high on the basis of tuberculin, anergy, and HIV test results. The cohort of 2212 IDUs was followed up for a median of 4.2 years; 25 IDUs, of whom 20 (80%) were infected with human immunodeficiency virus (HIV), developed TB. In an adjusted Cox proportional hazards model of high-risk IDUs, the risk of TB was associated with HIV infection (HR 10.3; 95% CI, 3.4-31.3); receipt of <6 months of isoniazid therapy (HR 7.6; 95% CI, 1.02-57.1); a CD4+ T lymphocyte count of <200 cells/mm3 (HR 6.6; 95% CI, 1.7-25.9); and tuberculin positivity (HR 4.0; 95% CI, 1.6-10.2). Treatment with isoniazid was beneficial in HIV-infected, tuberculin-positive IDUs.

AB - Injection drug users (IDUs) were heavily affected by the tuberculosis (TB) resurgence in New York City in the 1990s. We assessed the effectiveness of screening for latent TB infection in methadone users and of selective treatment with isoniazid. Risk for future TB was classified as low or high on the basis of tuberculin, anergy, and HIV test results. The cohort of 2212 IDUs was followed up for a median of 4.2 years; 25 IDUs, of whom 20 (80%) were infected with human immunodeficiency virus (HIV), developed TB. In an adjusted Cox proportional hazards model of high-risk IDUs, the risk of TB was associated with HIV infection (HR 10.3; 95% CI, 3.4-31.3); receipt of <6 months of isoniazid therapy (HR 7.6; 95% CI, 1.02-57.1); a CD4+ T lymphocyte count of <200 cells/mm3 (HR 6.6; 95% CI, 1.7-25.9); and tuberculin positivity (HR 4.0; 95% CI, 1.6-10.2). Treatment with isoniazid was beneficial in HIV-infected, tuberculin-positive IDUs.

UR - http://www.scopus.com/inward/record.url?scp=10744232287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744232287&partnerID=8YFLogxK

U2 - 10.1086/379513

DO - 10.1086/379513

M3 - Article

VL - 37

SP - 1686

EP - 1692

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 12

ER -